Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | THRB | P10828 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183280 | 0.92 | GAA (0.43) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL12230770 | 0.79 | KMT2A (0.37) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL148747 | 0.79 | GAA (0.42) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL19881771 | 0.79 | GAA (0.42) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL122852 | 0.79 | GAA (0.42) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL2757476 | 0.78 | KMT2A (0.39) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL17624206 | 0.78 | KMT2A (0.36) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL19881787 | 0.77 | GAA (0.41) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL15926059 | 0.75 | KMT2A (0.39) | GAASMN1; SMN2KMT2ATHRBCYP1A2 | |
| SCHEMBL5359897 | 0.74 | KMT2A (0.36) | GAASMN1; SMN2KMT2AKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2020-05-19 | — | — | US | disclosed |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2019-10-03 | — | — | US | disclosed |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| EP-3317287-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-07-31 | — | — | EP | disclosed |
| US-10239894-B2 | Inhibitors of indoleamine 2,3-dioxygenase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-26 | — | — | US | disclosed |
| US-20190040025-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-8993605-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
| US-8088803-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2012-01-03 | — | — | US | disclosed |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-10653677-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20190040025-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREFOR, AND APPLICATION | IDO1, IDO2, INMT | GAA 2026/4885SMN1; SMN2 4552/4885KMT2A 1148/4885 |
| US-20190298700-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20100015178-A1 | 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | GAA 1378/4885SMN1; SMN2 3781/4885KMT2A 792/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | GAA 1378/4885SMN1; SMN2 3781/4885KMT2A 792/4885 |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | GAA 2895/4885SMN1; SMN2 3837/4885KMT2A 1071/4885 |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, IDO1, IL2 | GAA 1889/4885SMN1; SMN2 3561/4885KMT2A 835/4885 |
| US-10239894-B2 | Inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | GAA 1028/4885SMN1; SMN2 4712/4885KMT2A 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.